Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Schering Pharma Kicks Off Life Quality Improvement Program For Bone Metastasis In Cancer Patients

This article was originally published in PharmAsia News

Executive Summary

Bayer Schering Pharma and Chinese Anti-Cancer Association recently kicked off the "dandelion program", which aims to promote the widespread adoption of the consensus on bone metastasis in malignant tumor and bone-related diseases diagnosis. The program will bring international updates of standardized treatment concepts to 2,000 clinical physicians to enrich their clinical experience in cancer treatment such as palliative treatment skills for active cancer symptoms and pain relief. At the same time, it will strengthen the capability of tumor patients and their relatives to identify false medical information and to understand relevant anti-cancer knowledge. (Click here for more - Chinese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071520

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel